晚期BRAFV600阳性黑色素瘤患者经维莫非尼联合考比替尼导入治疗3个月后早期转换为阿替利珠单抗导致肿瘤控制迅速丧失:ImmunoCobiVem 2期随机试验
ImmunoCobiVem 2期随机试验纳入185例初治晚期BRAFV600突变黑色素瘤患者,经维莫非尼联合考比替尼导入3个月后,135例无进展患者随机继续靶向治疗(A组,n=69)或转换为阿替利珠单抗(B组,n=66)。A组中位PFS1显著长于B组(13.9个月 vs 5.9个月;HR 0.55;95%CI 0.37-0.84;分层P=0.001),两组中位OS均未达到(HR 1.22;95%CI 0.69-2.16;分层P=0.389),2年OS B组67% vs A组58%。
要点
- 导入3个月后早期转换为阿替利珠单抗导致肿瘤控制迅速丧失,中位PFS1 5.9个月 vs 继续靶向治疗13.9个月(HR 0.55;95%CI 0.37-0.84;分层P=0.001)。
- 两组中位OS均未达到(HR 1.22;95%CI 0.69-2.16;分层P=0.389),2年OS B组67% vs A组58%。
- 3/4级不良事件A组55%、B组64%;治疗相关不良事件导致任一药物停用A组7%、B组9%。
核心结论
- 在经靶向治疗获得肿瘤控制的BRAFV600突变晚期黑色素瘤患者中,3个月时早期转换为阿替利珠单抗导致肿瘤控制迅速丧失,但与继续靶向治疗相比在2年时提供数值上的OS获益。
研究设计与样本
- 多中心2期随机试验,2016年11月至2019年12月入组185例初治晚期BRAFV600突变黑色素瘤患者,经维莫非尼联合考比替尼导入3个月后,135例无进展患者按1:1随机分为A组(继续维莫非尼联合考比替尼,n=69)和B组(转换为阿替利珠单抗,n=66),治疗至首次记录进展(PD1)。
- 主要结局为PFS1(从导入开始至PD1或死亡的时间),同时评估OS和安全性。
主要发现
- A组中位PFS1显著长于B组(13.9个月 vs 5.9个月;HR 0.55;95%CI 0.37-0.84;分层P=0.001)。
- 两组中位OS均未达到(HR 1.22;95%CI 0.69-2.16;分层P=0.389);2年OS B组67%(95%CI 53-78)vs A组58%(95%CI 45-70)。
- 3/4级不良事件A组55%、B组64%;治疗相关不良事件导致任一药物停用A组7%、B组9%。
关键数值与推荐
- A组中位PFS1 13.9个月 vs B组5.9个月(HR 0.55;95%CI 0.37-0.84;分层P=0.001)。
- 中位OS两组均未达到(HR 1.22;95%CI 0.69-2.16;分层P=0.389)。
- 2年OS B组67%(95%CI 53-78)vs A组58%(95%CI 45-70)。
- 3/4级不良事件A组55%、B组64%;治疗相关不良事件导致任一药物停用A组7%、B组9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: ImmunoCobiVem investigated whether a planned switch to atezolizumab after achieving tumour control during run-in with vemurafenib + cobimetinib improves progression-free survival (PFS) and overall survival (OS) compared to continuous targeted therapy (TT) in patients with previously untreated advanced BRAFV600-mutated melanoma. METHODS: In this multicenter phase 2 study, patients received vemurafenib plus cobimetinib. After 3months, patients without progressive disease (PD) were randomly assigned (1:1) to continue vemurafenib + cobimetinib (Arm A) or switch to atezolizumab (Arm B) until first documented PD (PD1). Primary outcome was PFS1 (time from start of run-in until PD1 or death). OS and safety were also assessed. RESULTS: Of 185 patients enroled between November 2016 and December 2019, 135 were randomly assigned after the run-in period (Arm A, n = 69; Arm B, n = 66). Median PFS1 was significantly longer in Arm A versus Arm B (13.9 versus 5.9months; hazard ratio [HR] 0.55; 95% confidence interval [CI], 0.37-0.84; PStratified=0.001). Median OS was not reached in either arm (HR 1.22; 95%CI, 0.69-2.16; PStratified=0.389); 2-year OS was higher in Arm B versus Arm A (67%; 95%CI, 53-78 versus 58%; 95%CI, 45-70). Grade 3/4 AEs occurred in 55% of patients in Arm A and 64% in Arm B; treatment-related AEs led to discontinuation of any drug in 7% and 9% of patients, respectively. CONCLUSION: In patients with BRAFV600-mutated advanced melanoma who achieve tumour control with TT, early switch at 3months to atezolizumab led to rapid loss of tumour control but provided a numerical OS benefit at 2years compared with continued TT.
引用
- Livingstone E, Gogas H, Kandolf-Sekulovic L, et al. Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial. Eur J Cancer. 2023. PMID: 37482012. doi:10.1016/j.ejca.2023.112941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。